(29 May, 2026, Shanghai China) 29 May 2026，Fosun Pharma (600196.SH; 02196.HK) today announced that the first participant in Chinese Mainland was dosed for the Phase 1 clinical trial of FXB0871, an PD-1-Targeted Attenuated IL-2 Fusion Protein Immunotherapy (ATTENUKINE™ *) developed in collaboration with Teva Pharmaceutical Industries Ltd. (Teva, NYSE & TASE: TEVA). This marks a significant milestone in the clinical development of this investigational, innovative drug in China, laying a critical foundation for the subsequent exploration of differentiated immuno-oncology combination therapies.

FXB0871 (TEV-56278 outside of Fosun Pharma’s territory) is a PD-1-Targeted Attenuated IL-2 Fusion Protein Immunotherapy (ATTENUKINE™), which is a cutting-edge technology. FXB0871 is designed to selectively deliver attenuated IL-2 to PD-1-positive T cells, thereby potentially enhancing T-cell anti-tumor activity while minimizing off-target systemic toxicity. Preclinical research data have demonstrated that the drug induces tumor regression, increases T-cell infiltration, and generates durable immune memory. To date, no IL‑2–based product with targeted delivery selectively directed to tumor-reactive T cells has been approved for launch globally.

Pursuant to the existing agreement between the parties, Fosun Pharma is granted an exclusive license to develop, manufacture and commercialize TEV-56278 in Chinese mainland, Hong Kong SAR, Macau SAR and Taiwan region and select Southeast Asian countries. The parties will share clinical data to jointly accelerate the research and development of this novel therapy. Currently, the international Phase 1 clinical study of TEV-56278/FXB0871 is ongoing in the United States and Canada.

As an innovation-driven global pharmaceutical and healthcare group, Fosun Pharma has established an open-ended and global innovation R&D system. Targeting unmet clinical needs, the Group has a deep presence in core therapeutic areas such as oncology, immunology and inflammation, and neurodegenerative diseases, while actively expanding into chronic diseases and rare diseases to build a product pipeline and integrated solutions with long-term competitiveness. At the same time, Fosun Pharma continues to strengthen its core technology platforms including antibodies and antibody-drug conjugates (ADCs), small molecules, and cell therapy, while expanding into cutting-edge technologies such as radiopharmaceuticals and small nucleic acids, reinforcing its early-stage innovation capabilities and accelerating the transformation of scientific discoveries

Going forward, Fosun Pharma will continue to focus on innovative R&D tracks, leveraging its well-established local clinical development system and professional R&D team to advance subsequent clinical trials in an orderly manner. Guided by clinical needs, the Company will accelerate the R&D and transformation of innovative drugs, continuously enrich its oncology pipeline, and strive to bring new, high-quality, and accessible treatment options to patients as soon as possible.

*ATTENUKINE™ is a registered trademark of Teva Pharmaceutical Industries Ltd.